Kornimate/medical-research-clean huggingface dataset:
improving health and wellbeing for people diagnosed with chronic spontaneous urticaria (csu)

Conditions: Chronic Spontaneous Urticaria

Summary: this study aims to investigate the influence of psychosocial factors on chronic spontaneous urticaria (csu). preliminary research suggests a potential link between stress and the experience of csu symptoms. in light of these findings, our study offers a stress management intervention for individuals diagnosed with csu. the intervention consists of a 6-week online course designed to cultivate effective stress management techniques, referred to as 'attention-based training (abt).' the course asks each participant to develop their own abt practice, along with a one-hour session per week, providing techniques that participants can use to combat stressors related to their condition.

chronic spontaneous urticaria (csu) is a common disorder that is poorly understood and frequently misdiagnosed. the burden of the disease can include stress, anxiety, sleep disturbances, and difficulty with activities of daily living. furthermore, psychological difficulties such as stress, may also aggravate the symptomatic burden of csu. holistic interventions are used as a complementary approach to alleviate symptoms in chronic diseases and may represent a valuable non-pharmacological approach in csu. in 2021, dr padraic dunne and colleagues published a feasibility assessment of an 8 week attention-based training programme to aid in the management of csu \[1\]. whilst this trial was deemed feasible and valuable for participants involved, further research was required with a wider sample to determine the role abt may have in the management of the condition. list of aims and objectives this current research aims to expand on their pilot study, and provide an evidence based non-pharmacological intervention to aid those in their management of csu. this project will be the one of the first to provide csu patients with a psychological intervention in conjunction with their clinical treatment. we believe that a combination of non-pharmacological and pharmacological solutions will ease the suffering caused by this condition and reduce the physical and fiscal burden on the irish health service and related clinics. this study will 1.) aim to identify the current psychosocial baseline of csu patients attending urticarial clinics in ireland and scotland, to further highlight the psychosocial experience of this population. 2.) provide and assess the effectiveness of an 6 week abt programme for csu management and patient wellbeing.

Eligibility criteria:
inclusion criteria: * must have diagnosis of csu exclusion criteria: * classified as a vulnerable adult cannot communicate online, in english
blood flow restriction & tennis elbow rehab

Conditions: Lateral Epicondylitis

Summary: lateral epicondylitis (le), often referred to as "tennis elbow" is a common and debilitating overuse injury affecting 1-3% of adults annually. le is most often defined as a syndrome of pain near the area of the lateral epicondyle of the elbow commonly effecting the origin of the extensor carpi radialis brevis with associated weakness; it most commonly effects the dominant arm. the best treatment for le is unknown and research to support current treatment methods are insufficient. a common limitation in functional recovery experienced by this population is pain at the lateral aspect of the elbow. as such, innovative therapeutic interventions directed at quickly reducing pain may address this unmet need and allow for improved outcomes, as well as earlier return to function.


Eligibility criteria:
inclusion criteria: 1. ages 18-65 years of age 2. diagnosis of lateral epicondylitis confirmed by the treating orthopaedic surgeon and ultrasound 3. must be able to read and write in english 4. able to provide own written consent exclusion criteria: 1. patients over 65 years of age 2. contralateral upper extremity involvement resulting in less than normal range of motion, muscle strength or daily pain greater than 1/10 3. history of prior injection for treatment of lateral epicondylitis 4. pregnancy 5. recent history of deep venous thrombosis (within the past 12 months) 6. active treatment with anticoagulants 7. history of upper quadrant lymph node dissection 8. history of endothelial dysfunction 9. patient history of easy bruising 10. active infection in the injured arm 11. cancer 12. uncontrolled peripheral vascular disease 13. uncontrolled diabetes mellitus
sglt2 inhibitors and reducing the risk of cancers among diabetics , an observational study

Conditions: Cancer; Diabetes Mellitus, Type 2; Interleukin 6; SGLT2 Inhibitors

Summary: since the discovery of sglt2 inhibitors, there is a great shift in diabetic treatment, so this drug is magic, this drug can reduce the blood sugar level by blocking the reabsorption of glucose in the kidney and increasing glucose excretion the first discovery by josef von mering who discovered the glucosuric effect of phlorizin. phlorizin is the progenitor of contemporary sglt2 inhibitors, the fda did not consider the work of baron josef von mering, since he had already discovered acidosis following the administration of phlorizin in 1888. now sglt2 inhibitors are used widely and even for heart failure without diabetes as this drug is useful and with lower risk of death from observational studies the 2008 fda guidance had a major impact on the cardiovascular (cv) risk assessment of recently approved antidiabetic drugs, many trials were done on sglt2 inhibitors like the empa-reg outcome trial, the canvas trial program, mace these groups have cvs benefits and also renal benefits as regards, we suspect long-term benefits and immunity aspect these groups play an important role in cancer incidence from meta-analysis and systematic review, suggests that sglt2 inhibition results in a reduction of inflammatory markers like interleukin-6 in animal models, further validating the suggested anti-inflammatory mechanism of action.

the map of treatment of diabetes and obesity was changed dramatically and newer drugs were discovered in the last 10 years for improving the quality of patients and prevent complications and cardiovascular and renal benefits from sglt2 inhibitors in our study, we will discuss the risk of cancer among diabetics on sglt2 inhibitors and measurement of inflammatory factors like crp and interleukin -6 alongside the other investigations the study included 200 adults patients with type 2 diabetes on sglt2 inhibitors and follow up these patients for one year for the inflammatory factors and risk of cancer among them and this study include patients from 18 years to 70 years having diabetes type 2 male or female, smoker or not smokers, non-diabetic ketoacidosis

Eligibility criteria:
inclusion criteria: * 18 -70 years male or female diabetics patients smoker or not smokers sglt-2 inhibitors no history of cancer no severe complications exclusion criteria: * diabetic ketoacidosis severe diseases pregnant type 1 diabetes
genetics of diabetes audit and research in tayside scotland (dolorisk dundee)

Conditions: Diabetic Neuropathic Pain

Summary: in 1997, the global prevalence of diabetes was estimated to be 125 million and this has risen to around 400 million in 2015. in addition diabetes has a number of complications including heart disease, blindness, kidney failure and amputation. this represents a significant burden on healthcare services. type 2 diabetes (t2d) is caused by a combination of genetic and environmental factors. the aim of godarts is to recruit participants with t2d to a registry to provide a platform with which to investigate the genetics of t2d, its complications and response to treatment. this study will investigate the genetic basis of diabetic neuropathic pain.

godarts is the genetics arm of the darts study, which was set up to identify all diabetes patients in the tayside region. its aim is to improve diabetes care over and above existing practices. participants are invited to attend to provide blood samples for dna/rna analysis, provide baseline anthropometric, biochemical, blood pressure and heart rate measurements as well as completing a lifestyle questionnaire containing smoking, menopausal and physical activity items. consent is also obtained to allow anonymous linkage to electronic medical records (emr) through use of the community health index (chi) number, a unique patient identifier that is issued to everyone registered with a general practitioner in scotland. godarts is the first emr linked cohort in the world and provides access to individual participant longitudinal data including biochemical, comorbidity and prescription records. these are live databases and are constantly being updated. this allows for the study of genetic factors influencing t2d, its comorbidities and response to therapy. consent has also been obtained for re-contact by collaborators, allowing for further studies of related phenotypes to take place. one of these studies is dolorisk dundee which aims to identify genetic and environmental risk factors for neuropathic pain.

Eligibility criteria:
inclusion criteria: * previous participation with godarts * existing consent to be recontacted * identified as being currently alive * currently has a postal address * age \> 18 years * neuropathic exclusion criteria: * unable to give consent * no current postcode * identified as having died
normal brain imaging database for brain disorder studies

Conditions: Healthy

Summary: healthy volunteers will be recruited. all subjects will be tested a battery of neuropsychological tests, then undergo fluorodeoxyglucose-positron emission tomography (pet) and magnetic resonance imaging (mri). during the pet and mri, they will be stimulated with transcranial direct current stimulation (tdcs) for 15 minutes. a third of subjects will receive real tdcs on the left prefrontal cortex, a third on the right prefrontal cortex, and the other third will receive sham tdcs.


Eligibility criteria:
inclusion criteria: * n/a exclusion criteria: * history of any neurological or psychiatric diseases; * abnormal mri; * metal implants or a cardiac pacemaker; * pregnant or breastfeeding women (female subjects of child bearing potential will be screened for pregnancy before mri imaging). * severe hypertension. * cardiovascular disease. * family history of epilepsy.
pk study in 3- to 6- month-old children (0476-268)(completed)

Conditions: Bronchiolitis

Summary: the purpose of this study is to look at the preliminary safety profile of an investigational drug in children 3 to 6 months of age with bronchiolitis.


Eligibility criteria:
inclusion criteria : * active bronchiolitis or a history of bronchiolitis and asthma-like symptoms exclusion criteria : * a history of any significant illness that will pose additional risk to the patient
using smart phone technology in detecting the presence of atrial fibrillation

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: the purpose of this study is to examine whether patients can use the alivecor case to record their heart rhythm and to assess the accuracy of the software in detecting af vs sinus rhythm

alivecor is a new monitoring technology used with a smart phone which allows patients to record their rhythm. the study will compare alivecor recordings and automated interpretation of the rhythm with the interpretation by an electrophysiologist.

Eligibility criteria:
inclusion criteria: 1. male or female between \> 18 and \< 80 years of age 2. paroxysmal or persistent atrial fibrillation 3. admitted for antiarrhythmic drug loading (dofetilide or sotalol) 4. already has iphone 4, 4s or 5 with data plan that accommodates the alivecor case 5. willing to use the alive cor case 6. written informed consent exclusion criteria: 1. unable or unwilling to use the alive cor case for their smart phone 2. presence of a permanent pacemaker
multiepitope peptide vaccination in melanoma

Conditions: Metastatic Melanoma

Summary: this trial assesses the clinical efficacy of a multiepitope peptide vaccine with gm-csf and klh as immunological adjuvants in stage iv melanoma patients


Eligibility criteria:
inclusion criteria: * metastatic melanoma * hla-a1, -a2, -a24, -b44 exclusion criteria:
typing proficiency following carpal tunnel release

Conditions: Carpal Tunnel Release

Summary: this study will investigate how soon a patient's typing proficiency returns to their pre-operative levels following carpal tunnel release surgery. in order to determine this, patients will undergo typing tests at different time points that will record their typing accuracy and speed. the results will then be compared to determine on average how soon a person returns to their pre-operative baseline results.

carpal tunnel syndrome is a condition in which the median nerve is compressed at the wrist. it causes such symptoms as numbness, tingling, weakness, muscle damage, and pain. if non-operative treatments do not work generally patients go on to carpal tunnel release surgery in which the transverse carpal ligament is released. after surgery patients usually return to work with no restrictions within six weeks. patients often ask how soon they are able to return to typing after surgery, and what their typing ability will be like after surgery. currently there are no studies that evaluate how long it takes for patient's typing skills to return to that of the pre-operative skill level. we would like to answer that question by comparing typing results from different time points including a baseline prior to surgery. we additionally seek to identify which patient characteristics are predictive of a faster return of typing proficiency. an additional innovative aspect of this project is the use of a web-based typing test that will be used in the assessment of patient typing proficiency. we will additionally use a web-based model for the collection of our survey data.

Eligibility criteria:
inclusion criteria: * patients set to undergo carpal tunnel release * patients who have a positive emg test * patients must have access to a computer with internet access * patients must have an email account * patients must be between the ages of 20-70 * patients that meet typing test requirements * must type weekly * typing proficiency of 30 wpm at time of pre-operative appointment * must use all fingers when typing * can read text in font times new roman size 14 exclusion criteria: * people who cannot read or write * people who do not meet inclusion criteria * patients who do not speak english * patients unwilling or unable to return for follow-up visits prescribed by the study protocol * patients who qualify for inclusion in the study, but refuse to participate. * patients with concurrent, ipsilateral confounding hand or upper extremity pathology such as trigger finger, ganglion cyst, painful arthritis, etc.
effect of dash diet and aerobic exercises on premenstrual syndrome

Conditions: Premenstrual Tension

Summary: hypothesis: there will be no effect of the dash diet and aerobic exercise on premenstrual syndrome. statement of the problem: do the dash diet and aerobic exercise have an effect on premenstrual syndrome?

for some women, symptoms of pms may be so severe that they miss work or school. physical activity is a suitable method for the treatment of pms and is the best method for all women to reduce pressure and balance the brain's chemical secretion. it seems that physical activity by increasing endorphins and reducing adrenal cortisol leads to the improvement of symptoms of pms. dash diet has been suggested to play an important role in the development, and treatment of some psychological disorders. for instance, it has been reported that a diet rich in fish, folate, and b-vitamins can alleviate the manifestations of depression. an established association was also shown between the dietary glycemic index (gi) and psychological diseases, depressive disorder, and mental functioning. diets containing of "junk foods" (high energy and low nutritional) have been shown to increase the risk of mental illness, but a healthy diet is associated with less depressive symptoms and can improve mood .

Eligibility criteria:
inclusion criteria: * fifty adolescent females were diagnosed with premenstrual syndrome. * their age will be ranged from 15-to 25 years (3 years post-puberty). * their body mass index (bmi) will range from 18-25.9 kg/m2. * all are of regular menstrual cycles. * all of them suffer from moderate and severe pms. exclusion criteria: * any pathologic findings in the pelvic cavity as a polycystic ovarian syndrome, endometriosis, and pelvic inflammatory diseases. * having irregular menstruation. * any metabolic diseases. * any history of gynecological intervention.
clinical trial to evaluate pharmacokinetic interaction of atb-1011 and atb-1012 in healthy adult volunteers

Conditions: Healthy Adult Volunteers

Summary: to evaluate the interaction between two investigational products by comparing and analyzing pharmacokinetic interactions and safety in steady state after multiple oral administration of atb-1011 or atb-1012 alone or in combination in healthy adult volunteers.

* arm a: to evaluate the effect of atb-1012 on the safety and pharmacokinetic properties of atb-1011 in steady state. * arm b: to evaluate the effect of atb-1011 on the safety and pharmacokinetic properties of atb-1012 in steady state.

Eligibility criteria:
inclusion criteria: 1. those who are over 19 years old at the screening visit 2. those with a body mass index (bmi) between 18.0 kg/m2 and 30.0 kg/m2 with a weight of 50 kg or more (45 kg or more for women) at the screening visit 3. those who do not have clinically significant congenital or chronic diseases and have no pathological symptoms or findings upon medical examination at the screening visit 4. those who determined as suitable study subjects by the principal investigator (or a delegated sub-investigator) in result of planned and conducted laboratory tests such as hematology, blood chemistry, serum, and urine tests according to the characteristics of the investigational product. exclusion criteria: - 1) those who have a clinically significant disease or have a history of such disease in the digestive system, cardiovascular system, endocrine system, respiratory system, blood/tumor, infectious diseases, kidney and genitourinary system, mental and nervous system, musculoskeletal system, immune system, otorhinolaryngology, skin system and ophthalmic system. 2) those who have a history of gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect the absorption of drugs or have gastrointestinal diseases 3) those who have taken drugs that induce and inhibit metabolism enzymes such as barbital drugs within 1 month of the first administration date, or have taken drugs that may interfere with this clinical trial within 10 days of the first administration date. (however, participation is possible depending on the characteristics of pharmacokinetics and pharmacodynamics such as interactions with investigational products or half-life of concomitant drugs) 4) those who participated in other clinical trials or bioequivalence studies and administered the investigational products within 6 months of the first administration date.
targeting dopamine therapy in rls

Conditions: Restless Legs Syndrome

Summary: neurons in the brain require blood and oxygen for proper function. the term "neurovascular coupling" has been postulated in the 19th century by roy \& sherrington referring to increased blood flow to active neurons. the rationale of this research relies on the neurovascular coupling, suggesting that increased blood flow to active regions on the brain should supply not only more blood, but also more of a pharmacological agent present in the blood system at the time. thus, active regions should be affected by the agent (=drug) to a greater extent. in the present study we focus on the dopaminergic system, critical in many functions such as cognition, response to stimuli and movement. one of the well-known dopaminergic pathways in the brain is the nigrostriatal pathway, mediating motor function. in this research, we intend to examine the effects of coupling functional activation in this pathway with a dopaminergic agent, carbidopa/levodopa, on symptoms of restless leg syndrome (rls). rls is characterized by an irresistible urge to move the limbs (i.e. akathisia), and results most prominently by a significant decrease in the quality of sleep. our research focuses on this symptom of rls to examine the effect of coupling brain activation and drug treatment. the first line of treatment in rls is dopaminergic drugs. these drugs increase dopamine levels in motor pathways, and our research will aim to couple activation in the nigrostriatal motor pathway with dopaminergic treatment in rls. functional activation will be achieved with a simple motor task, known to elicit activation in the nigrostriatal pathway. we hypothesize that the drug will act upon the pre-activated motor system, and that this coupling between brain activation and drug treatment will ameliorate sleep-related symptoms of rls, compared with treating these symptoms solely with a dopaminergic drug and compared with using a non-motor task.


Eligibility criteria:
inclusion criteria: rls diagnosis according the common clinical criteria no known neurological illnesses no known kidney illnesses no known iron deficiency no history of drug or alcohol use exclusion criteria: regular drug treatment use of a psychotropic substance in the two weeks prior to the study auditory or visual impairment psychiatric history neurological illness chronic kidney illness obstructive sleep apnea (osa) dopaminergic drug intolerance or sensitivity glaucoma melanoma or pre-melanoma (current or previous) pregnancy
comparison of the effect of a-prf and l-prf on outcomes after removal of impacted mandibular third molar

Conditions: Pain, Postoperative; Trismus; Swelling

Summary: in this study, it was aimed to investigating and comparing the postoperative effects of leukocyte- and platelet-rich fibrin (l-prf) and advanced platelet-rich fibrin (a-prf) in terms of pain, swelling on the cheek, and trismus after mandibular third molar surgery. the study included a total of 27 patients with bilateral impacted mandibular third molar which surgically operated at different times. patients were evaluated in two randomly separated groups. for the first group; a-prf and for the second group; l-prf was applied into the tooth socket. the outcomes variables were; pain, swelling, the number of analgesics taken, and trismus. these variables were also assessed on the basis of; 1st, 2nd, 3rd and 7th days following the operation.


Eligibility criteria:
inclusion criteria: * age≥18 * the presence of bilaterally symmetrically impacted mandibular third molar, which requires an extraction for prophylactic reasons * absence of systemic diseases * absence of chronic opioid taken; * not being pregnant * not smoking and no alcohol usage * the absence of allergy to penicillin or any other drugs used during standardized postoperative therapy. exclusion criteria: * tooth needed to be sectioning during the operation * operation time exceeding 30 minutes * the cases with severe periodontal disease or acute pericoronitis, * the cases using antibiotics for an existing infection * the cases not capable of following postoperative instructions

Keywords: leukocyte- and platelet rich fibrin advanced platelet rich fibrin impacted mandibular third molar surgery